Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,077 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Active Product 1 Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced Sep 4, 2026, 9:53 AM EDT
Completed Phase 1 Interventional Results available

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

NCT03388632
View directory record Official record
Conditions
Metastatic Solid Tumors, Treatment-Refractory Cancers
Interventions
rhIL-15, Ipilimumab, Nivolumab, Tumor biopsies, EKG, ECHO, CT Scan
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 4, 2026, 9:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

NCT04393298
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ginisortamab, trifluridine/tipiracil, mFOLFOX6
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Charleston, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 4, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

NCT02873936
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, csDMARDs
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
55
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 4, 2026, 9:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microbicides Acceptability Among Sexually Active Young Women

NCT00490152
View directory record Official record
Conditions
HIV Infections
Interventions
Automated diary system
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
2
States / cities
Tampa, Florida • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Sep 4, 2026, 9:53 AM EDT
Recruiting Early Phase 1 Interventional

FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer

NCT04174352
View directory record Official record
Conditions
ERα+ Breast Cancer, ESR1 Gene Mutation
Interventions
Tamoxifen, FES PET/CT
Drug · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
19 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 4, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

NCT04052698
View directory record Official record
Conditions
Von Willebrand Diseases
Interventions
Wilate
Drug
Lead sponsor
Octapharma
Industry
Eligibility
6 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Sep 4, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Fontan Udenafil Exercise Longitudinal Assessment Trial

NCT02741115
View directory record Official record
Conditions
Single Ventricle Heart Disease
Interventions
Udenafil, Placebo
Drug
Lead sponsor
Mezzion Pharma Co. Ltd
Industry
Eligibility
12 Years to 18 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
26
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Sep 4, 2026, 9:53 AM EDT
Recruiting Phase 2 Interventional

Prazosin for Alcohol Use Disorder With Withdrawal Symptoms

NCT04793685
View directory record Official record
Conditions
Alcohol Withdrawal
Interventions
Prazosin, 12-Step Facilitation with Relapse Prevention and Contingency Management
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 4, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Preoperative Skin Preparation Evaluation

NCT00636480
View directory record Official record
Conditions
Topical Antisepsis
Interventions
Chlorhexidine gluconate, ChloraPrep One Step, Sterile saline
Drug
Lead sponsor
C. R. Bard
Industry
Eligibility
16 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 4, 2026, 9:53 AM EDT
Completed Not applicable Interventional

Goal Setting for Health Behavior and Psychosocial Issues in Primary Care

NCT01825746
View directory record Official record
Conditions
Health Behaviors, Obesity, Substance Abuse, Anxiety, Depression
Interventions
Implementation of the MOHR assessment in primary care workflow
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 75 Years
Enrollment
3,591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
8
States / cities
Los Angeles, California • Chapel Hill, North Carolina • Portland, Oregon + 5 more
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Sep 4, 2026, 9:53 AM EDT
Terminated Phase 3 Interventional Results available

A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

NCT04927247
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions
Inclacumab, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 4, 2026, 9:53 AM EDT
Withdrawn Not applicable Interventional

Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication

NCT00006578
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Abacavir sulfate, Amprenavir, Lamivudine, Filgrastim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Denver, Colorado • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2015 · Synced Sep 4, 2026, 9:53 AM EDT
Completed Phase 1Phase 2 Interventional

Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy

NCT00957918
View directory record Official record
Conditions
Parkinson's Disease
Interventions
nicotine, placebo comparator
Drug · Other
Lead sponsor
Neuraltus Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 83 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angelis, California • Oxnard, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Sep 4, 2026, 9:53 AM EDT
Completed Phase 4 Interventional Results available

Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection

NCT03512210
View directory record Official record
Conditions
Hepatitis C, HIV-1-infection, Liver Diseases
Interventions
Sofosbuvir/Velpatasvir (SOF/VEL), Minimal Monitoring (MINMON) Strategy
Drug · Other
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Sep 4, 2026, 9:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults

NCT01115920
View directory record Official record
Conditions
Healthy
Interventions
MTP-131 (Bendavia™)
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 17, 2010 · Synced Sep 4, 2026, 9:53 AM EDT
Completed Phase 1Phase 2 Interventional

Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors

NCT05142592
View directory record Official record
Conditions
Safety Issues, Tolerability, Pharmacokinetics
Interventions
IPG7236
Drug
Lead sponsor
Nanjing Immunophage Biotech Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 4, 2026, 9:53 AM EDT
Withdrawn Phase 2 Interventional

A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders

NCT05974293
View directory record Official record
Conditions
NMO Spectrum Disorder, Spasticity, Muscle
Interventions
Nabiximols, Placebo
Drug
Lead sponsor
Michael, Levy M.D.,Ph.D.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 4, 2026, 9:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects

NCT02637193
View directory record Official record
Conditions
Healthy Subjects
Interventions
Venlafaxine, Moxifloxacin, Drug - placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 4, 2026, 9:53 AM EDT
Suspended Phase 1 Interventional

2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML

NCT06626633
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
CRD3874
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 4, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder

NCT02395978
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
PDC-1421 Capsule, placebo
Drug
Lead sponsor
BioLite, Inc.
Industry
Eligibility
20 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 4, 2026, 9:53 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib

NCT00582660
View directory record Official record
Conditions
Colorectal Adenoma, Colorectal Carcinoma
Interventions
Celecoxib, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Sep 4, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2

NCT03566238
View directory record Official record
Conditions
PFIC1, PFIC2
Interventions
A4250 (odevixibat), Placebo
Drug
Lead sponsor
Albireo
Industry
Eligibility
6 Months to 18 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 4, 2026, 9:53 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Autonomic Determinants of POTS - Pilot1

NCT04050410
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
Moxonidine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 4, 2026, 9:53 AM EDT